ClinicalTrials.gg
CompletedNCT00335699Updated Dec 17, 2007

Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic Syndrome

A Phase 4 interventional study of Rosuvastatin in Hypercholesterolemia, sponsored by AstraZeneca. Completed at 7 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-12-17.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
370
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 59 studies testing rosuvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. rosuvastatin · Hypercholesterolemia.

Enrollment
26th of 57
370 · median 203
Started
2005
with 1 other
Phase 4
15 of 59
none open now
Registered
10th of 59
by date
Lead sponsor
25 of 59
AstraZeneca

Among the 59 studies testing rosuvastatin in Hypercholesterolemia, this one is the 26th largest by enrollment of the 57 interventional ones that give a count, is one of 2 that started in 2005, is one of 15 in phase 4, and was the 10th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 59 studies testing rosuvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 59 studies testing rosuvastatin in Hypercholesterolemia as a file.
02

Study summary

The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg in the percentage reduction of LDL-C in Subjects with metabolic syndrome after 6 weeks of treatment.

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • Hypercholesterolemia with nondiabetic metabolic syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Metabolic syndrome patient; Presence of 3 or more of the following:

    • Abdominal obesity (waist circumference): men > 90cm(36 inch), women > 80cm(32 inch)
    • Triglycerides ≥ 150 mg/dL (1.70 mmol/L)
    • HDL-C: men \< 40 mg/dL (1.04 mmol/L), women \< 50 mg/dL (1.3 mmol/L)
    • BP ≥130/≥85 mmHg or subject receiving anti-hypertensive treatment
    • Fasting blood glucose 110 mg dL (6.11 mmol/L) - 125 mg/dL (6.94 mmol.L)
  • Elevated LDL-C concentrations reported within 4 weeks of visit 1 as follows;

    • ≥ 130 mg/dL (3.36 mmol/L) to \< 220 mg/dL (5.69 mmol/L) in statin naive subjects (subjects who have not taken any lipid-lowering therapy known to affect LDL-C in the 4 weeks prior to visit 1)
    • ≥ 100 mg/dL (2.59 mmol/L) to \< 160 mg/dL (4.14 mmol/L) in subjects who have taken a lipid lowering drug(s) within 4 weeks of visit 1
  • Triglyceride levels \< 400 mg/dL (4.52 mmol/L)
  • Women of should be using a medically acceptable form of chemical or mechanical .

Exclusion criteria

Exclusion Criteria:

  • History of known diabetes mellitus
  • Use of anti-hyperglycaemic medication.
  • History of serious or reactions to HMG-CoA reductase inhibitors, in particular history of myopathy.
  • No CHD or CHD Risk Equivalents and 0-1 Risk factors and Framingham 10-Year risk is \<10%.
  • History of heterozygous or homozygous familial hypercholesterolaemia or known type III hyperlipoproteinaemia (familial dysbetalipoproteinaemia).
  • Active arterial disease such as unstable angina pectoris, myocardial infarction, (TIA), cerebrovascular accident (CVA), coronary artery bypass surgery (CABG) or angioplasty within 2 months prior to entry in the dietary lead in period
  • Uncontrolled hypothyroidism defined as thyroid stimulating hormone (TSH) > 1.5 times the (ULN) at Visit 2 or subjects whose thyroid replacement therapy was initiated within 3 months of entry into dietary lead-in phase.
  • Current active liver disease ( [ALT] > 2 x ULN) or severe hepatic impairment.
  • Unexplained serum CK >3 times ULN (e.g. not due to recent trauma, intramuscular injections, heavy exercise, etc).
  • Serum creatinine > 176 umol/L (2.0 mg/dL)
  • History of alcohol, or drug, abuse or both.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
370 participants

Interventions

06

What researchers measure

Primary outcomes

  1. The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg in the percentage reduction of LDL-C in Subjects with metabolic syndrome after 6 weeks of treatment.

Secondary outcomes

  1. The secondary objectives of this study are to compare the effects of rosuvastatin 10mg with atorvastatin 10mg in subjects with metabolic syndrome, after 6weeks of treatment, on:

  2. Bringing subjects to their established NCEP ATP III target goals for LDL-C

  3. Bringing subjects to their non-HDL target goal(based on NCEP-ATP III criteria)

  4. Modifying other lipids and lipid ratios

  5. Modifying inflammatory markers

  6. Glucose and insulin resistance

  7. Safety

07

Study locations

7 sites
  • Research Site
    DaeGu, Korea, Republic of
  • Research Site
    IkSan, Korea, Republic of
  • Research Site
    JeonJu, Korea, Republic of
  • Research Site
    JinJu, Korea, Republic of
  • Research Site
    KwangJu, Korea, Republic of
  • Research Site
    Pusan, Korea, Republic of
  • Research Site
    Ulsan, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005 and a completion of Jan 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2006
First posted
Jun 12, 2006
Start
Aug 2005
CompletionActual
Jan 2007
Last update
Dec 17, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00335699
Lead sponsor
AstraZeneca
First posted
Jun 12, 2006
Start date
Aug 2005
Completion
Jan 2007
Last update
Dec 17, 2007

Study contacts

AstraZeneca Korea Medical Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion